342 related articles for article (PubMed ID: 29767640)
1. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older.
Ranzani A; Oreni L; Agrò M; van den Bogaart L; Milazzo L; Giacomelli A; Cattaneo D; Gervasoni C; Ridolfo AL
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):193-201. PubMed ID: 29767640
[TBL] [Abstract][Full Text] [Related]
2. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.
Tseng A; Szadkowski L; Walmsley S; Salit I; Raboud J
Ann Pharmacother; 2013 Nov; 47(11):1429-39. PubMed ID: 24285760
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.
Marzolini C; Elzi L; Gibbons S; Weber R; Fux C; Furrer H; Chave JP; Cavassini M; Bernasconi E; Calmy A; Vernazza P; Khoo S; Ledergerber B; Back D; Battegay M;
Antivir Ther; 2010; 15(3):413-23. PubMed ID: 20516560
[TBL] [Abstract][Full Text] [Related]
4. Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team.
Molas E; Luque S; Retamero A; Echeverría-Esnal D; Guelar A; Montero M; Guerri R; Sorli L; Lerma E; Villar J; Knobel H
HIV Clin Trials; 2018 Feb; 19(1):1-7. PubMed ID: 29179644
[TBL] [Abstract][Full Text] [Related]
5. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors.
Deutschmann E; Bucher HC; Jaeckel S; Gibbons S; McAllister K; Scherrer AU; Braun DL; Cavassini M; Hachfeld A; Calmy A; Battegay M; Cipriani M; Elzi L; Young J; Lopez-Centeno B; Berenguer J; Khoo S; Moffa G; Marzolini C;
Clin Infect Dis; 2021 Oct; 73(7):e2145-e2152. PubMed ID: 32634832
[TBL] [Abstract][Full Text] [Related]
7. Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.
Halloran MO; Boyle C; Kehoe B; Bagkeris E; Mallon P; Post FA; Vera J; Williams I; Anderson J; Winston A; Sachikonye M; Sabin C; Boffito M
Antivir Ther; 2019; 24(3):193-201. PubMed ID: 30700636
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, beliefs and impact of drug-drug interactions between antiretroviral therapy and illicit drugs among people living with HIV in Spain.
Castro-Granell V; Garin N; Jaén Á; Cenoz S; Galindo MJ; Fuster-RuizdeApodaca MJ
PLoS One; 2021; 16(11):e0260334. PubMed ID: 34797882
[TBL] [Abstract][Full Text] [Related]
9. Potential drug-drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan.
Kunimoto Y; Matamura R; Ikeda H; Fujii S; Kimyo T; Kitagawa M; Nakata H; Kobune M; Miyamoto A; Fukudo M
J Pharm Health Care Sci; 2021 Dec; 7(1):43. PubMed ID: 34847955
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study: Can dual ART mitigate the risk of potential drug-drug interactions among PLWH under stable ART?
Inkaya AÇ; Balli FN; Kara E; Demirkan K; Ünal S
Turk J Med Sci; 2023; 53(5):1505-1511. PubMed ID: 38813033
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda.
Eneh PC; Hullsiek KH; Kiiza D; Rhein J; Meya DB; Boulware DR; Nicol MR
BMC Infect Dis; 2020 Aug; 20(1):572. PubMed ID: 32758158
[TBL] [Abstract][Full Text] [Related]
12. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.
Holtzman C; Armon C; Tedaldi E; Chmiel JS; Buchacz K; Wood K; Brooks JT;
J Gen Intern Med; 2013 Oct; 28(10):1302-10. PubMed ID: 23605401
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Polypharmacy and Potential Drug-Drug Interactions Associated with Risk Factors in the Era of HIV Integrase Inhibitors: A Prospective Clinical Study.
Altunal LN; Yagcı Caglayık D; Ozel AS; Tukenmez Tigen E; Sili U; Erturk Sengel B; Aydın M; Korten V
AIDS Patient Care STDS; 2023 Mar; 37(3):138-145. PubMed ID: 36812461
[TBL] [Abstract][Full Text] [Related]
14. [Predictive factors of clinically significant drug-drug interactions among regimens based on protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir].
Cervero M; Torres R; Jusdado JJ; Pastor S; Agud JL
Med Clin (Barc); 2016 Apr; 146(8):339-45. PubMed ID: 26971988
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients.
Jakeman B; Nasiri M; Ruth L; Morse C; Mahatme S; Patel N
Ann Pharmacother; 2017 May; 51(5):365-372. PubMed ID: 28367698
[TBL] [Abstract][Full Text] [Related]
16. Potential drug-drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey.
Tinggaard M; David KP; Gerstoft J; Hansen AE; Kirk O; Lebech AM; Lindhardt BØ; Rose MV; Ryom L; Weis N; Benfield T
HIV Med; 2023 Jan; 24(1):46-54. PubMed ID: 35521975
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach.
Iniesta-Navalón C; Franco-Miguel JJ; Gascón-Cánovas JJ; Rentero-Redondo L
HIV Med; 2015 May; 16(5):273-9. PubMed ID: 25523089
[TBL] [Abstract][Full Text] [Related]
18. Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study.
Secoli SR; Figueras A; Lebrão ML; de Lima FD; Santos JL
Drugs Aging; 2010 Sep; 27(9):759-70. PubMed ID: 20809665
[TBL] [Abstract][Full Text] [Related]
19. Ageing with HIV: medication use and risk for potential drug-drug interactions.
Marzolini C; Back D; Weber R; Furrer H; Cavassini M; Calmy A; Vernazza P; Bernasconi E; Khoo S; Battegay M; Elzi L;
J Antimicrob Chemother; 2011 Sep; 66(9):2107-11. PubMed ID: 21680580
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey.
Igho-Osagie E; Brzozowski K; Jin H; Brown J; Williams MG; Puenpatom A
Clin Ther; 2023 May; 45(5):390-399.e4. PubMed ID: 37032225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
